COMMENTARY

• Did Voice of the Industry Reach Honebuto Policymakers?
  June 21, 2017

• As AG Momentum Continues, Mucosta AG to Hit Shelves 8 Years after Gx Entry
  June 14, 2017

• MHLW, MOF Agreed on CEFP Working Group Report, Continuation of Premium As-Is Seems Difficult
  May 11, 2017

• Will Government Take the Lead in Pricing Debate towards 2017 Fiscal Blueprint?
  April 19, 2017

• “Cash-and-Carry Dealers” and Their Peculiar Business Practices in the Spotlight in Wake of Counterfeit Harvoni Scandal
  April 12, 2017

• Is the Government’s 70% Interim Generic Share Target Achievable?
  March 13, 2017

• Growing Hopes for Control of Hepatic Cancer; Road to Cures for Hepatitis B, NASH Might Be in Sight
  March 7, 2017

• Will NHI Pricing Reform in Sluggish Domestic Market Trigger Industry Reorganization?
  February 6, 2017

• Top-Notch Talents Needed for Pharma’s Lobbying Activities; Stay Current with Policymaking Moves
  January 30, 2017

• Hepatology Society Revises Hep C Treatment Guidelines; Looking to Future Research for Non-Responders to IFN-Free Treatment
  December 14, 2016

• Taltz Issue Exposes Forex-Sensitive Nature of Drug Pricing System
  November 15, 2016

• Are Biosimilars on Verge of Breakthrough in Japan? Initiatives Underway to Prepare for Full-Scale Entry of Major Biosimilars
  October 25, 2016

• Policymakers Face Balancing Act over Opdivo Re-Pricing
  October 17, 2016

• Can Wholesalers Bear Distribution Costs amid 90% Discount on Generics?
  October 11, 2016

• Can Mid-sized Makers Break Away from Long-Listed Product Model?
  August 19, 2016

• MHLW’s Feat to Link Drug Review and Reimbursement Policies Put to Test with “Expensive Drugs”
  June 28, 2016

• 7 Drugs Picked for Cost-Effective Assessments, but Now How Will They Be Re-Priced Exactly?
  May 27, 2016

• Data Corroborate Harshness of Z2 Rule, Only Handful to Escape 2nd Consecutive Application
  March 31, 2016

• Global Pharmas Casting Colder Eyes on Japan Market; PhRMA, EFPIA to Up Lobbying Efforts with Govt, Ruling Parties
  March 11, 2016

• Companies Can “Veto” Humanitarian Trials for Legitimate Reasons; Cooperation Is Essential, but Access Scheme Shouldn’t Stymie Main Development
  February 23, 2016

ページ